Enterokinase Light Chain Solubility via Hydrophilic Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant bovine enterokinase in E.coli result in low yields and inefficient processes due to aggregation and poor solubility of the enzyme, leading to expensive and low-specific-activity products.
Innovation Solution
Development of a bovine enterokinase light chain analogue with specific mutations (C112A, L134K, and I135K) to enhance solubility and refolding efficiency, allowing for improved production processes and increased yields by mutating hydrophobic surface amino acids to hydrophilic ones, and using a method involving culturing host cells, recovering inclusion bodies, solubilizing, and refolding the enzyme.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If enterokinase is produced as soluble protein in E.coli, then the purification process becomes simpler, but the yield is low and the product mixture contains both soluble and insoluble protein requiring expensive affinity columns
Solution Approach 1:
The invention extracts the problematic hydrophobic amino acids from the enterokinase surface and replaces them with hydrophilic alternatives. This selective extraction and replacement of specific residues (e.g., Leu134, Ile135, Phe142) transforms the protein's surface properties, enabling high-yield soluble production without requiring complex affinity chromatography purification steps.
Solution Approach 2:
The invention changes the chemical parameters of the protein surface by substituting hydrophobic amino acids with hydrophilic ones. This parameter change in surface hydrophobicity fundamentally alters the solubility characteristics of enterokinase, allowing it to remain soluble at high concentrations and eliminating the need for expensive affinity columns while dramatically increasing production yield.
2Ease of manufacture
If enterokinase is produced as insoluble inclusion bodies, then the isolation becomes easier, but the refolding process is challenging with possible aggregation and low satisfactory yields
Solution Approach 1:
The invention applies preliminary anti-action by pre-modifying the amino acid sequence to prevent aggregation before it occurs. By replacing surface hydrophobic residues with hydrophilic alternatives, the protein is engineered to resist the aggregation tendency that normally occurs during inclusion body formation and refolding, thereby enabling high-yield recovery without aggregation problems.
Solution Approach 2:
The invention changes the surface hydrophobicity parameter of enterokinase by substituting hydrophobic residues with hydrophilic ones. This parameter change fundamentally alters the protein's behavior during refolding, preventing aggregation and enabling high refolding yields from inclusion bodies while maintaining the ease of isolation.
3Reliability
If commercial enterokinase products are used, then the process is established, but the products are expensive and of low specific activity due to inefficient renaturation or secretion
Solution Approach 1:
The invention performs preliminary action by pre-engineering the enterokinase sequence with hydrophilic substitutions before production. This preliminary modification ensures that the protein will naturally exhibit high solubility and activity during production, eliminating the inefficiencies of post-production renaturation or secretion steps that plague commercial products, thereby achieving high specific activity at lower cost.
Solution Approach 2:
The invention changes the surface hydrophobicity parameter of enterokinase to improve its production characteristics. This parameter change enables the protein to be produced with high specific activity through simpler processes, avoiding the inefficient renaturation and secretion steps that limit commercial products, thereby reducing cost while maintaining reliability.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention is related to novel mammalian enterokinase analogues such as mammalian enterokinase light chain analogues and methods of making such. Also described herein is a method for cleaving proteins having an enterokinase cleavage site.